文献速递关节外科创伤骨科

依诺肝素与阿司匹林相比是否与持续性伤口引流风险更高相关?CRISTAL随机试验数据的二次分析

Is Enoxaparin Associated With a Higher Risk of Persistent Wound Drainage Than Aspirin? A Secondary Analysis of Data From the CRISTAL Randomized Trial.
PubMed 文献 · Clin Orthop Relat Res · 2023-01-17

该研究为CRISTAL随机试验的二次分析,纳入1339例髋或膝关节置换患者,比较依诺肝素与阿司匹林对持续性伤口引流的影响。总体两组持续性伤口引流比例无差异(9% vs 8%),但在皮下缝合亚组中依诺肝素与更高风险相关(OR 3.6),作者提醒该亚组样本量小需谨慎解读。

要点

  • 总体持续性伤口引流比例依诺肝素组9% vs 阿司匹林组8%,无显著差异(OR 1.2,95%CI 0.8-1.8;p=0.40)。
  • 皮下缝合亚组中依诺肝素与更高持续性伤口引流风险相关(OR 3.6,95%CI 1.5-10.6;p=0.009),但样本量小。
  • 两组6个月内关节相关再手术风险无差异(2.4% vs 2.2%,OR 1.1,95%CI 0.5-2.4;p=0.86)。

核心结论

  • 对于全部纳入患者,依诺肝素与阿司匹林相比未增加持续性伤口引流风险。
  • 对于接受皮下缝合的患者,依诺肝素可能与更高引流风险相关,但鉴于该分析样本量小,应谨慎解读。
  • 无论使用何种预防措施,引流持续时间均较短,且依诺肝素未增加关节相关再手术风险。
  • 这些发现不应妨碍临床医生在髋或膝关节置换术后使用依诺肝素进行静脉血栓栓塞预防。

研究设计与样本

  • 本研究为一项整群随机试验的二次分析,该试验通过澳大利亚骨科协会国家关节置换登记处开展,数据来自其中两家参与医院。
  • 根据试验分配序列,两家参与医院被随机分配为所有髋关节置换患者术后35天、所有膝关节置换患者术后14天给予阿司匹林(每日100 mg)或依诺肝素(每日40 mg)作为静脉血栓栓塞预防。
  • 在达到第一组患者入组目标后交叉至另一预防组。
  • 2019年4月至2020年12月,1679例合格患者中1339例纳入本研究;依诺肝素组纳入合格患者的82%(707/861),阿司匹林组纳入77%(632/818)。
  • 两组平均年龄均为67±10岁,平均BMI为32±7 kg/m²;依诺肝素组男性比例(43%[302/707] vs 36%[227/632];p=0.01)、髋关节置换比例(36%[254/707] vs 29%[182/632];p=0.006)及皮下缝合比例(62%[441/707] vs 33%[208/631];p<0.001)均高于阿司匹林组。

主要发现

  • 依诺肝素组与阿司匹林组持续性伤口引流比例无差异(9%[65/707] vs 8%[49/632],OR 1.2[95%CI 0.8-1.8];p=0.40)。
  • 在皮下缝合患者中,控制年龄、性别、BMI、术前抗凝药使用及关节置换类型等混杂变量后,依诺肝素与更高持续性伤口引流风险相关(OR 3.6[95%CI 1.5-10.6];p=0.009)。
  • 在皮肤钉缝合患者中,控制相同变量后,依诺肝素与持续性伤口引流风险无关(OR 1.1[95%CI 0.7-1.9];p=0.66)。
  • 在发生持续性伤口引流的患者中(共114例:依诺肝素组65例,阿司匹林组49例),达到干性伤口的中位时间无差异(依诺肝素组1天[IQR 1-2天] vs 阿司匹林组1天[IQR 1-3天];p=0.22)。
  • 6个月内关节相关再手术风险在依诺肝素组(2.4%[17/707])与阿司匹林组(2.2%[14/632])之间无差异(OR 1.1[95%CI 0.5-2.4];p=0.86)。

关键数值与推荐

  • 持续性伤口引流定义为术后第3天之后的任何伤口引流。
  • 对于发生持续性伤口引流的患者,达到干性伤口的时间定义为术后第3天之后伤口变干所需的天数。
  • 证据等级为III级,治疗性研究。

临床怎么用

  • 作者认为这些发现不应妨碍临床医生在髋或膝关节置换术后使用依诺肝素进行静脉血栓栓塞预防。

局限性

  • 皮下缝合亚组分析样本量小,作者指出该发现应谨慎解读。
  • 评估者未对患者接受的预防类型设盲。
  • 本研究为二次分析,数据仅来自原试验两家参与医院。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Owing to its association with prosthetic joint infection, persistent wound drainage has become an important clinical entity after THA or TKA. The association between venous thromboembolism (VTE) prophylaxis and persistent wound drainage has not been extensively reported before but has potentially important clinical implications. QUESTIONS/PURPOSES: (1) Is the type of VTE prophylaxis (enoxaparin or aspirin) used after hip arthroplasty or knee arthroplasty associated with a higher risk of persistent wound drainage? (2) In patients who experience persistent wound drainage, is the type of VTE prophylaxis associated with a longer time taken to achieve a dry wound? (3) Is type of VTE prophylaxis associated with a higher risk of joint-related reoperation within 6 months? METHODS: This was a secondary analysis of data from an earlier cluster-randomized trial conducted through the Australian Orthopaedic Association National Joint Replacement Registry; data were drawn from two participating hospitals from that study. According to the trial's allocation sequence, the two participating hospitals were randomized to administer aspirin (100 mg daily) or enoxaparin (40 mg daily) as VTE prophylaxis to all patients undergoing hip arthroplasty for 35 days after the procedure and for all patients undergoing knee arthroplasty for 14 days afterwards. Crossover to the alternate prophylaxis group occurred after the patient enrollment target had been met for the first arm. Between April 2019 and December 2020, 1339 of 1679 eligible patients were included in this study; 82% (707 of 861) of eligible patients were allocated to the enoxaparin group and 77% (632 of 818) of eligible patients we allocated to the aspirin group. The mean age in both groups was 67 ± 10 years and the mean BMI was 32 ± 7 kg/m 2 . There was a higher proportion of male patients (43% [302 of 707] versus 36% [227 of 632]; p = 0.01), hip arthroplasties (36% [254 of 707] versus 29% [182 of 632]; p = 0.006), and patients receiving subcuticular closure (62% [441 of 707] versus 33% [208 of 631]; p < 0.001) in the enoxaparin group than in the aspirin group. Patients were monitored for wound drainage on each postoperative day until discharge, and this was recorded in the medical record once per day. Assessors were not blinded to the type of prophylaxis each patient received. Persistent wound drainage was defined as any wound drainage beyond Postoperative Day 3. For patients who experienced persistent wound drainage, the time taken to achieve a dry wound was defined as the number of days beyond Postoperative Day 3 for the wound to become dry. Logistic regression was used to determine whether the prophylaxis type was associated with persistent wound drainage. For patients with persistent wound drainage, the median time of drainage was compared between groups using the Kruskal-Wallis test. The number of patients undergoing a joint-related reoperation within 6 months was identified through data linkage to the Australian Orthopaedic Association National Joint Replacement Registry and electronic record review, and was compared using a Fisher exact test. RESULTS: We found no difference between the enoxaparin and aspirin groups in terms of the percentage of patients who had persistent wound drainage (9% [65 of 707] versus 8% [49 of 632], odds ratio 1.2 [95% confidence interval 0.8 to 1.8]; p = 0.40). For patients receiving subcuticular closure, after controlling for other potentially confounding variables, including age, sex, BMI, preoperative anticoagulant use, and type of arthroplasty, enoxaparin was associated with a higher risk of persistent wound drainage than aspirin (OR 3.6 [95% CI 1.5 to 10.6]; p = 0.009). For patients receiving a skin staple closure, after controlling for the same variables above, we found enoxaparin was not associated with a higher risk of persistent wound drainage (OR 1.1 [95% CI 0.7 to 1.9]; p = 0.66). For patients who experienced persistent wound drainage patients (114: 65 in the enoxaparin group and 49 in the aspirin group), there was no difference in the median (interquartile range) time taken to achieve a dry wound (enoxaparin: 1 day [IQR 1 to 2 days], aspirin: 1 day [IQR 1 to 3 days]; p = 0.22). There was no difference in the risk of joint-related reoperation within 6 months between enoxaparin (2.4% [17 of 707]) and aspirin (2.2% [14 of 632], OR 1.1 [95% CI 0.5 to 2.4]; p = 0.86). CONCLUSION: Enoxaparin was not associated with an increased risk of persistent wound drainage compared with aspirin for all patients included in this study. Enoxaparin may be associated with a higher risk of drainage for patients receiving subcuticular closure. However, this finding should be interpreted cautiously, given the small sample size in this analysis. The duration of drainage was short regardless of the prophylaxis used, and enoxaparin was not associated with an increased risk of joint-related reoperation. These findings should not deter clinicians from using enoxaparin for VTE prophylaxis after hip or knee arthroplasty. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Sidhu VS, Naylor JM, Adie S, et al. Is Enoxaparin Associated With a Higher Risk of Persistent Wound Drainage Than Aspirin? A Secondary Analysis of Data From the CRISTAL Randomized Trial. Clin Orthop Relat Res. 2023. PMID: 36649465. doi:10.1097/CORR.0000000000002544

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。